Go Back to Match Results for ""
E1A11; Randomized Phase III Trial of Bortezomib Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib Lenalidomide Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Study Overview
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma.
Study Description
The purpose of this study is to compare the overall survival between two strategies of lenalidomide maintenance following induction with a proteasome inhibitor-IMiD (lenalidomide) combination: limited duration of maintenance (24 months) versus indefinite maintenance therapy until disease progression.
Additional Information
- IRB Number: 1312871111 (E1A11)
- Research Study Identifier: TX3873
- Principal Investigator: Rafat Abonour, MD
